Equities Analysts Offer Predictions for INO Q3 Earnings

Key Points

• HC Wainwright revised their earnings per share (EPS) forecast for Inovio Pharmaceuticals' Q3 2025 from ($0.57) to ($0.54), while maintaining a "Neutral" rating and a $3.00 price objective.
• Inovio Pharmaceuticals recently posted quarterly earnings of (0.61) EPS, outperforming the consensus estimate of (0.63) EPS by $0.02.
• The stock has seen significant interest from institutional investors, with multiple new positions established in recent quarters, reflecting a growing belief in its long-term potential.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) - HC Wainwright lifted their Q3 2025 earnings estimates for Inovio Pharmaceuticals in a report issued on Thursday, August 14th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.54) per share for the quarter, up from their previous estimate of ($0.57). HC Wainwright currently has a "Neutral" rating and a $3.00 target price on the stock. The consensus estimate for Inovio Pharmaceuticals' current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals' Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.09) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at $0.28 EPS and FY2026 earnings at ($1.33) EPS.

Several other research analysts have also recently commented on INO. Wall Street Zen cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $5.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 14th. Piper Sandler initiated coverage on Inovio Pharmaceuticals in a research report on Wednesday, July 9th. They set an "overweight" rating and a $5.00 price objective for the company. Finally, Oppenheimer reduced their target price on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Inovio Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $8.80.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock traded up $0.05 during trading hours on Monday, reaching $1.96. 2,281,732 shares of the company were exchanged, compared to its average volume of 1,789,629. Inovio Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $7.76. The stock's fifty day moving average is $1.65 and its 200 day moving average is $1.83. The firm has a market cap of $104.15 million, a PE ratio of -0.75 and a beta of 1.38.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last released its earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.02.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Large investors have recently bought and sold shares of the business. Deep Track Capital LP lifted its position in Inovio Pharmaceuticals by 72.9% in the fourth quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company's stock valued at $5,708,000 after acquiring an additional 1,314,796 shares during the last quarter. Stonepine Capital Management LLC purchased a new stake in Inovio Pharmaceuticals in the fourth quarter valued at $1,922,000. Bank of America Corp DE lifted its position in Inovio Pharmaceuticals by 1,035.2% in the fourth quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company's stock valued at $1,173,000 after acquiring an additional 584,521 shares during the last quarter. Geode Capital Management LLC lifted its position in Inovio Pharmaceuticals by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company's stock valued at $1,150,000 after acquiring an additional 6,874 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Inovio Pharmaceuticals in the fourth quarter valued at $412,000. Hedge funds and other institutional investors own 26.79% of the company's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.